Food and Drug Administration · Forecast
Studies Addressing Rare Neurodegenerative Diseases including ALS
What it funds
The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development.
How to apply
Read the full notice and application package on the official listing, FOR-FD-25-006 on Grants.gov. Questions go to terrin.brown@fda.hhs.gov. Make sure your SAM.gov registration and Grants.gov or agency portal accounts are active well before the deadline, since registration can take several weeks.
Last updated by the agency Aug 14, 2024. Tracked by Federal Runway since Nov 17, 2026. Confirm details on the official notice.